Most metabolic compounds target pathways you already know — appetite signaling, growth hormone secretion, fatty acid transport. 5-Amino-1MQ targets an enzyme most people have never heard of: nicotinamide N-methyltransferase (NNMT), a metabolic bottleneck in fat cells that quietly siphons away the raw material the body needs to produce NAD+. It is not a peptide — it is an orally bioavailable small molecule that works at the level of intracellular energy programming in adipose tissue itself.

All current evidence is preclinical. In diet-induced obesity mice, NNMT knockdown conferred resistance to obesity without affecting food intake or lean mass. 5-Amino-1MQ specifically reduced body weight and fat mass through increased adipocyte energy expenditure. No human clinical trials have been published. What does exist is a growing body of user reports — roughly 130 across Reddit threads — showing polarized but informative results: energy and endurance improvements are the most consistent positive signal, fat-loss outcomes vary sharply by user profile, and the salt form of the compound may explain many "it didn't work" reports.

What Is 5-Amino-1MQ?

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of NNMT. It is not a peptide — it is a synthetic compound with molecular formula C10H12N2O and molecular weight 176.21 g/mol. By blocking NNMT in adipose tissue, it prevents the enzyme from diverting nicotinamide away from the NAD+ salvage pathway, preserving a key substrate for cellular energy production in fat cells. Unlike most recomposition compounds, which are peptides requiring subcutaneous injection, it is orally bioavailable: it crosses the cell membrane and directly inhibits a cytosolic enzyme. NNMT only emerged as a serious metabolic target in the last decade — a landmark 2014 Nature study identified it as a key regulator of adipocyte energy balance.

The NNMT Enzyme — Why It Matters for Fat Metabolism

NNMT is a cytosolic enzyme that methylates nicotinamide using S-adenosylmethionine (SAM, the cell's primary methyl donor), producing a methylated form that cannot be used for energy metabolism and consuming SAM in the process. In obesity it is significantly overexpressed in white adipose tissue, creating a dual resource drain: nicotinamide is diverted away from the NAD+ salvage pathway, and SAM is consumed (reducing methylation capacity). Lower NAD+ means reduced sirtuin activity — the NAD+-dependent deacetylases regulating mitochondrial biogenesis, fatty-acid oxidation, and thermogenesis. The net effect is an adipocyte reprogrammed to favor energy storage over expenditure. The enzyme's activity scales with obesity: more visceral fat, higher NNMT expression, lower adipocyte NAD+ — a self-reinforcing loop that appetite- or substrate-based interventions do not touch.

How NNMT Inhibition Shifts Cellular Energy

When 5-Amino-1MQ inhibits NNMT, more nicotinamide remains available for conversion to NAD+ via the salvage pathway (NAMPT → NMN → NAD+), elevating intracellular NAD+ specifically in adipocytes without added precursors. Downstream, elevated NAD+ activates Sirt1, enhances AMPK signaling, and increases mitochondrial density and function — shifting the fat cell from storage-dominant toward energy expenditure. Critically, preserving SAM keeps methyl groups available for DNA methylation, histone modification, and epigenetic regulation. This dual preservation — nicotinamide for NAD+ and SAM for methylation — makes NNMT inhibition mechanistically distinct from simply adding NAD+ precursor. In the Neelakantan 2018 study, the compound reduced body weight and fat mass without affecting food intake or lean mass.

The Energy Signal: What Restored NAD+ Feels Like

This mitochondrial upregulation may explain the most consistent community signal: energy and endurance improvement, often noticed before any measurable body-composition change. Users describe it consistently — endurance "without muscle loss," "significant energy improvement" when adding 50 mg to a GLP-1 protocol, and dose-dependent "too much energy" at higher injectable doses. Energy appears before composition because mitochondrial biogenesis is upstream and fat oxidation is the downstream consequence. This reframes 5-Amino-1MQ from "fat-loss compound" to a metabolic reprogram that makes fat cells energy-producing rather than energy-hoarding, with endurance as the earliest signal.

The NAD+ Connection — A Different Entry Point

Most NAD+ strategies add precursor (NMN, NR) — pouring more water into the system. 5-Amino-1MQ plugs the drain instead, stopping NNMT from siphoning nicotinamide before NAMPT can use it. The approaches are complementary, not competing: NMN increases system-wide supply; 5-Amino-1MQ reduces local loss in tissues where NNMT is overexpressed (predominantly white adipose tissue). Because adipocyte NAD+ directly influences sirtuin-mediated programs determining lipid storage versus oxidation, even adequate systemic NMN may not compensate for the local deficit when NNMT is draining nicotinamide in obese adipose tissue. Blocking NNMT addresses the tissue-specific problem at its source.

Preclinical Research Highlights

The preclinical evidence is consistent and reproducible across models; no human trials are published.

Kraus et al., 2014 (Nature): antisense knockdown of NNMT in white adipose tissue protected high-fat-diet mice against obesity, with increased energy expenditure and reduced adipocyte size — repositioning NNMT from a drug-metabolism enzyme to a metabolic target. Neelakantan et al., 2017 (J Med Chem): structure-activity work establishing 5-Amino-1MQ as a potent, selective NNMT inhibitor. Neelakantan et al., 2018 (Biochem Pharmacol): the most body-composition-relevant study — diet-induced obesity mice showed significant reductions in body weight and fat mass, with food intake and lean mass unaffected; fat loss was attributed to increased adipocyte energy expenditure. Hong et al., 2015 (Sci Rep): extended NNMT to hepatic nutrient handling via Sirt1 stabilization. Ulanovskaya et al., 2013 (Nat Chem Biol): established NNMT's role in metabolism and epigenetics through a methylation-sink mechanism.

Where 5-Amino-1MQ Fits in an Optimized Protocol

For someone already running metabolic compounds, 5-Amino-1MQ addresses a non-overlapping pathway.

Each compound addresses a distinct node: GLP-1 reduces intake centrally, MOTS-c reprograms fuel selection, L-carnitine solves transport, tesamorelin addresses the GH axis. 5-Amino-1MQ works at intracellular NAD+ availability in white adipose tissue. Community stacking centers on two combinations — MOTS-c + 5-Amino-1MQ (AMPK flexibility plus NAD+ preservation) and GLP-1 + 5-Amino-1MQ (appetite reduction plus adipocyte energy expenditure) — both targeting non-overlapping nodes.

Practical Considerations

Practitioner-reported protocols use 50–150 mg orally per day, taken in the morning, in cycles of 4–6 weeks on and 8–12 weeks off — figures from practice literature and community reporting, not clinical dose-finding. A common approach starts at 50 mg daily for one to two weeks to assess tolerance before increasing to 100–150 mg. Oral dosing is a practical advantage: no reconstitution or injection. Commonly reported side effects are headaches (most frequent) and irritability, usually in the first week and often resolving; persistent headache warrants dose reduction or discontinuation. NNMT is also expressed in the liver, relevant context for the conservative cycle lengths given the absence of long-term clinical safety data.

Who Responds — and Who Doesn't

Across 130+ user reports, positive responders tend to be already lean (sub-15% body fat), running optimized training/nutrition/sleep, and using the chloride salt at adequate doses. The ~40% reporting no effect skew toward higher body fat, shorter durations, and possibly the lower-potency iodide salt. This is not a compound that overrides a poor baseline — it targets a specific bottleneck (NNMT) that becomes more relevant as other variables are optimized.

Chloride vs Iodide — Salt Form Matters

5-Amino-1MQ is sold as the chloride salt (HCl, ~212.67 g/mol; active base ~83% per mg) or the iodide salt (HI, ~304.13 g/mol; active base ~58% per mg). A 150 mg iodide dose delivers ~87 mg active compound; the same 150 mg of chloride delivers ~125 mg — a 44% potency gap from salt form alone. This may explain a meaningful fraction of negative reports; chloride is preferred for dose accuracy.

Insomnia Is the Mechanism Working

Insomnia is the most commonly reported side effect and the most misunderstood. If the compound is raising NAD+ and mitochondrial function, elevated evening energy is the mechanism working, not an adverse effect. The fix is timing, not dose reduction: take the full dose in the morning. Users who switch from split or afternoon dosing to a single morning dose consistently report the insomnia resolving.